Swiss pharmaceutical giant Novartis AG has announced a major exit from its listed Indian arm! On February 20, 2026, the company confirmed it will sell its entire 70.68% stake in Novartis India Limited (NIL) — the Mumbai-listed entity — to a private equity-led consortium for approximately ₹1,446 crore (about $159 million). This marks Novartis’ full divestment from the subsidiary as part of a broader global strategic restructuring.
The deal triggered an immediate stock rally: Novartis India shares zoomed up to 20% in early trading on BSE, hitting highs around ₹996.50 before settling with strong gains (closing context from prior day at ₹830.45, with premium pricing).
For Mumbai investors and pharma watchers, this is big news — especially since NIL focuses on innovative medicines for diabetes, chronic neurological, cardiological, and dermatological conditions. The transaction won’t affect Novartis Healthcare Pvt Ltd (NHPL), the separate unlisted entity handling commercial ops, corporate center in Hyderabad, and R&D/clinical trials across 300+ sites.
Key Deal Details
- Stake Sold: 70.68% (entire controlling stake held by Novartis AG).
- Buyer Consortium: Led by WaveRise Investments, alongside ChrysCapital Fund X (a top Indian PE firm with pharma portfolio like Intas, Eris Lifesciences) and Two Infinity Partners.
- Deal Value: ₹1,446 crore for the 70.68% stake, at ₹860.64 per share — a 3.6% premium to the previous closing price.
- Mandatory Open Offer: The consortium must launch an open offer for the remaining 26% public shareholding at the same ₹860.64 per share, potentially adding over ₹552 crore in value for public shareholders.
- Post-Deal Changes: Novartis AG will cease control and hold no shares in NIL. The company may undergo a name change (subject to regulatory and shareholder approvals). NIL is expected to evolve into a pure-play innovative medicines company with an adapted footprint for long-term sustainable growth aligned with global strategies.
Background & Reasons for the Exit
Novartis initiated a strategic review of its stake in NIL about two years ago (around 2024) to unlock shareholder value. This follows the earlier spin-off of Sandoz (generics/biosimilars business) in 2023, allowing Novartis to focus on innovative drugs. The sale is part of that ongoing restructuring — NIL and NHPL have been separate entities, with no operational impact on NHPL from this deal.
No direct executive quotes were highlighted in reports, but the move aligns with Novartis’ global push for efficiency and focused growth in high-value areas.
Market Reaction & Implications for India (2026)
- Stock Performance: Shares surged nearly 18-20% on announcement day (February 20, 2026), reflecting investor optimism about new ownership and potential value unlocking under PE management.
- For Investors: Public shareholders get a premium exit option via the open offer. ChrysCapital’s entry (its first majority pharma stake in India) signals confidence in NIL’s portfolio and growth potential in chronic therapies.
- Pharma Sector: Highlights continued PE interest in India’s pharma space, especially established listed players with strong brands in diabetes/cardio/neuro segments.
This deal is subject to customary approvals and closing conditions. Novartis will maintain its strong India presence through NHPL’s R&D, clinical trials, and commercial operations.
Mumbai stock market folks — are you holding Novartis India shares or eyeing the open offer? What’s your take on ChrysCapital taking control — bullish for growth or just a value unlock? Share in the comments, especially if you’re tracking pharma stocks from Bandra or BKC!
(Updated February 20, 2026, ~2:00 PM IST – based on The Hindu, Reuters, Economic Times, Morningstar, and exchange filings. Stock prices and availability subject to market changes.) 💼